Buchumschlag

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

The feasibility and efficacy of a combination of thalidomide, cyclophosphamide, etoposide, and dexamethasone were studied in 56 patients with poor-prognosis multiple myeloma. Of 50 patients evaluable for response, 4% achieved complete response (CR), 64% partial response (PR), 18% minimal response (M...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Möhler, Thomas (VerfasserIn) , Neben, Kai (VerfasserIn) , Benner, Axel (VerfasserIn) , Egerer, Gerlinde (VerfasserIn) , Krasniqi, Fatime (VerfasserIn) , Ho, Anthony Dick (VerfasserIn) , Goldschmidt, Hartmut (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: [December 15, 2001]
In: Blood
Year: 2001, Jahrgang: 98, Heft: 13, Pages: 3846-3848
ISSN:1528-0020
DOI:10.1182/blood.V98.13.3846
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.V98.13.3846
Volltext
Verfasserangaben:Thomas M. Moehler, Kai Neben, Axel Benner, Gerlinde Egerer, Fatime Krasniqi, Anthony D. Ho, and Hartmut Goldschmidt
Beschreibung
Zusammenfassung:The feasibility and efficacy of a combination of thalidomide, cyclophosphamide, etoposide, and dexamethasone were studied in 56 patients with poor-prognosis multiple myeloma. Of 50 patients evaluable for response, 4% achieved complete response (CR), 64% partial response (PR), 18% minimal response (MR), 6% stable disease (SD), and 8% progressive disease (PD), resulting in an objective response rate (≥ MR) of 86.0% (76.7% overall objective response rate in intent-to-treat analysis; n = 56). Subsequent to successful remission induction, 18 patients received autologous or allogeneic stem cell transplantation. The median progression-free survival in all patients was 16 months. The median overall survival time could not be calculated, since the last observed death occurred after 16 months of follow-up (median follow-up of 14 months) with a corresponding estimated survival probability of 55%. Severe adverse effects (World Health Organization III/IV) included infectious complications (35.7%) and cardiovascular events (7.1%). The data suggest that Thal improves antitumor activity of salvage chemotherapy regimens in poor-prognosis multiple myeloma.
Beschreibung:Gesehen am 01.03.2022
Beschreibung:Online Resource
ISSN:1528-0020
DOI:10.1182/blood.V98.13.3846

Ähnliche Einträge